AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
ledipasvir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals, hepatitis C Virus (HCV) NS5A inhibitors | 4899 | 1256388-51-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
an inhibitor of the HCV NS5A protein, which is required for viral replication
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Hosey CM, Chan R, Benet LZ |
| S (Water solubility) | 0.10 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 76 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 5.150 | High | 0.80 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 16.943 | High | 0.80 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.181 | 10^-6 cm/s | High | 0.80 |
| dh-clint | Dog hepatocyte intrinsic clearance | 3.981 | uL/min/10^6 cells | High | 0.80 |
| dppb | Dog plasma protein binding (% unbound) | 0.180 | % | High | 0.80 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.170 | % | High | 0.80 |
| herg | hERG pIC50 | 4.909 | pIC50 | High | 0.80 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.923 | uL/min/10^6 cells | High | 0.80 |
| hlm-clint | Human liver microsomal intrinsic clearance | 5.929 | uL/min/mg protein | High | 0.80 |
| hppb | Human plasma protein binding (% unbound) | 0.170 | % | High | 0.80 |
| kinase-safety-class | ACVR2B,GRK2,PDK1,PDK2,PDK4 | 5 | |||
| kinase-selectivity-class | CLK4,PDK1 | 2 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 21.184 | High | 0.80 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 7.228 | High | 0.80 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.150 | High | 0.80 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 33.037 | High | 0.80 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 | |||
| pppb | Pig plasma protein binding (% unbound) | 0.090 | % | High | 0.80 |
| rh-clint | Rat hepatocyte intrinsic clearance | 2.328 | uL/min/10^6 cells | High | 0.80 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 0.250 | % | High | 0.80 |
| rppb | Rat plasma protein binding (% unbound) | 0.140 | % | High | 0.80 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 1.135 | uM | High | 0.80 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 10, 2014 | FDA | GILEAD SCIENCES INC | |
| Dec. 4, 2014 | EMA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | 93.45 | 56.35 | 19 | 257 | 8175 | 42612884 |
| Complications of transplanted lung | 57.77 | 56.35 | 8 | 268 | 329 | 42620730 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | 109.35 | 78.44 | 24 | 1030 | 9856 | 110578389 |
| Complications of transplanted lung | 93.25 | 78.44 | 14 | 1040 | 683 | 110587562 |
| Amaurosis fugax | 89.02 | 78.44 | 16 | 1038 | 2374 | 110585871 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AP51 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
| FDA EPC | N0000191256 | Hepatitis C Virus NS5A Inhibitor |
| CHEBI has role | CHEBI:36044 | antiviral drug |
| CHEBI has role | CHEBI:64924 | hepatitis C protease inhibitor |
Related Drugs by ATC class:
J05AP Antivirals for treatment of HCV infections 18 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic hepatitis C | indication | 128302006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.48 | acidic |
| pKa2 | 13.1 | acidic |
| pKa3 | 13.41 | acidic |
| pKa4 | 13.92 | acidic |
| pKa5 | 6.07 | Basic |
| pKa6 | 5.39 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 8334270 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 8580765 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 8735372 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 9085573 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 8334270 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 8580765 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 8735372 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 9085573 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8334270 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8580765 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8735372 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 9085573 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8334270 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8580765 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8735372 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 9085573 | March 21, 2028 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 7964580 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 8633309 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 8889159 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 7964580 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 8633309 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 8889159 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 7964580 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8633309 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8889159 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 7964580 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8633309 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8889159 | March 26, 2029 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 8273341 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 8822430 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 8841278 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 9511056 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 8273341 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 8822430 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 8841278 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 9511056 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8273341 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8822430 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8841278 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 9511056 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8273341 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8822430 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8841278 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 9511056 | May 12, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 9284342 | Sept. 13, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 9284342 | Sept. 13, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 9284342 | Sept. 13, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 9284342 | Sept. 13, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 8618076 | Dec. 11, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 8618076 | Dec. 11, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8618076 | Dec. 11, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 8618076 | Dec. 11, 2030 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 9393256 | Sept. 14, 2032 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 9393256 | Sept. 14, 2032 | FOR THE TREATMENT OF HEPATITIS C |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 9393256 | Sept. 14, 2032 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | 9393256 | Sept. 14, 2032 | FOR THE TREATMENT OF HEPATITIS C |
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | 10039779 | Jan. 30, 2034 | FOR THE TREATMENT OF HEPATITIS C |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 10039779 | Jan. 30, 2034 | FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | 10039779 | Jan. 30, 2034 | FOR TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION FOR A DURATION OF 8-WEEKS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 45MG;200MG | HARVONI | GILEAD SCIENCES INC | N205834 | Aug. 28, 2019 | RX | TABLET | ORAL | Aug. 28, 2026 | FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S). AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S) |
| 90MG;400MG | HARVONI | GILEAD SCIENCES INC | N205834 | Oct. 10, 2014 | RX | TABLET | ORAL | Aug. 28, 2026 | FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S). AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S) |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | Aug. 28, 2026 | TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | Aug. 28, 2026 | TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN |
| 33.75MG;150MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | Aug. 28, 2026 | TREATMENT OF PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | Aug. 28, 2026 | TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | Aug. 28, 2026 | TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN |
| 45MG;200MG/PACKET | HARVONI | GILEAD SCIENCES INC | N212477 | Aug. 28, 2019 | RX | PELLETS | ORAL | Aug. 28, 2026 | TREATMENT OF PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Genome polyprotein | Polyprotein | INHIBITOR | EC50 | 11.40 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Genome polyprotein | Polyprotein | INHIBITOR | EC50 | 10.51 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Nonstructural protein 5A | Unclassified | EC50 | 10.51 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 013TE6E4WV | UNII |
| D10442 | KEGG_DRUG |
| 4033796 | VUID |
| N0000191095 | NUI |
| 4033796 | VANDF |
| C3851350 | UMLSCUI |
| CHEMBL2374220 | ChEMBL_ID |
| 67505836 | PUBCHEM_CID |
| DB09027 | DRUGBANK_ID |
| 9796 | INN_ID |
| C586541 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11271 | IUPHAR_LIGAND_ID |
| 1591922 | RXNORM |
| 30602 | MMSL |
| d08295 | MMSL |
| 015709 | NDDF |
| 712517005 | SNOMEDCT_US |
| 714387002 | SNOMEDCT_US |
| CHEBI:85089 | CHEBI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Harvoni | HUMAN PRESCRIPTION DRUG LABEL | 2 | 61958-1801 | TABLET, FILM COATED | 90 mg | ORAL | NDA | 35 sections |
| Harvoni Access | HUMAN PRESCRIPTION DRUG LABEL | 2 | 61958-1802 | TABLET, FILM COATED | 90 mg | ORAL | Export only | 31 sections |
| Harvoni | HUMAN PRESCRIPTION DRUG LABEL | 2 | 61958-1803 | TABLET, FILM COATED | 45 mg | ORAL | NDA | 35 sections |
| Harvoni | HUMAN PRESCRIPTION DRUG LABEL | 2 | 61958-1804 | PELLET | 45 mg | ORAL | NDA | 35 sections |
| Harvoni | HUMAN PRESCRIPTION DRUG LABEL | 2 | 61958-1805 | PELLET | 33.75 mg | ORAL | NDA | 35 sections |
| Ledipasvir and Sofosbuvir | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72626-2601 | TABLET, FILM COATED | 90 mg | ORAL | NDA AUTHORIZED GENERIC | 34 sections |